Arylsulfonylamino hydroxamic acid derivatives
CA 2264284 A1 · Owner: Robinson, Ralph P. · Inventors: Robinson, Ralph P.; Blumenkopf, Todd A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I) wherein n, X R3, R4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration restenosis, periodontal disease, epidermolysis bullosa scleritis, and other diseases , characterized by matrix metalloproteinase activity AIDS, sepsis, septic shock , and other diseases involving the production of TNF. In addition the compounds , of the present invention may be used in combination therapy with standard nonsteroidal anti-inflammatory drugs (NSAID'S) and analgesics and in combination , with cytotoxic drugs such as adriamycin daunomycin, cis-platinum, etoposide, taxol …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 25, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 25, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 25, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.